Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 04 2023
26 04 2023
Historique:
received:
25
07
2022
accepted:
29
03
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
epublish
Résumé
With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. The current study was a randomized, parallel, double-blind, placebo-controlled trial. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients' status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries. Initial viral loads were log
Identifiants
pubmed: 37100830
doi: 10.1038/s41598-023-32546-z
pii: 10.1038/s41598-023-32546-z
pmc: PMC10132439
doi:
Substances chimiques
Nasal Sprays
0
azelastine
ZQI909440X
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6839Informations de copyright
© 2023. The Author(s).
Références
Acta Pharmacol Sin. 2021 Aug;42(8):1347-1353
pubmed: 33116249
Lancet Respir Med. 2020 Sep;8(9):e70
pubmed: 32771081
Biochem Biophys Res Commun. 2021 Jan 29;538:173-179
pubmed: 33309272
Front Pharmacol. 2022 Jun 30;13:861295
pubmed: 35846988
Pharmacol Rep. 2023 Apr;75(2):249-265
pubmed: 36848033
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Virol J. 2021 Jun 2;18(1):110
pubmed: 34078394
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Inflammopharmacology. 2021 Oct;29(5):1357-1360
pubmed: 34279767
Pharmaceutics. 2022 Nov 18;14(11):
pubmed: 36432693
Viruses. 2020 Dec 03;12(12):
pubmed: 33287245
Sci Rep. 2022 Jan 18;12(1):899
pubmed: 35042866
Expert Rev Anti Infect Ther. 2021 Oct;19(10):1325-1330
pubmed: 33759682
Elife. 2021 Sep 27;10:
pubmed: 34569939
Viruses. 2021 May 12;13(5):
pubmed: 34066046
J Infect. 2021 Aug;83(2):237-279
pubmed: 33992687
Bioinformation. 2020 Mar 31;16(3):236-244
pubmed: 32308266
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
N Engl J Med. 2021 Feb 18;384(7):671-673
pubmed: 33503337
Nat Med. 2022 May;28(5):1031-1041
pubmed: 35361992
Expert Opin Pharmacother. 2007 Apr;8(5):701-9
pubmed: 17376024
Struct Chem. 2020;31(6):2487-2499
pubmed: 32837119
Front Pharmacol. 2019 Mar 29;10:294
pubmed: 31001114
Infect Drug Resist. 2022 Dec 21;15:7529-7536
pubmed: 36575672
J Patient Rep Outcomes. 2022 Mar 26;6(1):26
pubmed: 35348945
Pharmaceutics. 2022 Sep 27;14(10):
pubmed: 36297492
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Intern Emerg Med. 2022 Mar;17(2):359-367
pubmed: 34133005
Ann Allergy Asthma Immunol. 1996 May;76(5):469-75
pubmed: 8630722
JAMA Otolaryngol Head Neck Surg. 2021 Apr 1;147(4):400-401
pubmed: 33538761
ACS Med Chem Lett. 2020 Oct 25;11(12):2526-2533
pubmed: 33324471